Conneticut 3/7/2013 10:56:45 PM
News / Stocks

Best of Drug Manufacturers-Other Industry: Amarin (AMRN), Prana (PRAN), Teva Pharmaceutical (TEVA)

Amarin Corporation plc (ADR) (NASDAQ:AMRN) gained +7.95% to close at $8.42

universalpennystocks.com focus is on Hot Penny Stocks that trade on OTCBB and OTC markets, which are mostly referred to as “penny stocks”. These Penny Stocks could offer the greatest potential return on your short or long term investment. Sign up for our free newsletter before you miss the next alert.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) gained +7.95% to close at $8.42 and its overall volume in the last trading session was 6.73 million shares, beating the average volume of 3.38 million. Analysts at Roth Capital recently reiterated their buy rating but reduced price target on the stock from $17.00 to $16.00. AMRN hit the day high price of $8.69 and day low of $7.79.

The stock is trading with positive year-to-date performance of +4.08%. It has current ratio of 7.04 and its debt-to-equity ratio is 3287.25. The company has total market cap of $1.26billion.

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) jumped +7.39% with the closing price of $2.47 after unveiling plan to present its lead drug candidate for Parkinson's Disease (PD) and movement disorders, PBT434, at two international conferences in March. The key result to be released is that PBT434 decreases the aggregation and accumulation of a key protein (alpha-synuclein) in three transgenic animal models of the disease.

The overall volume in the last trading session was 2.25 million shares. Its fifty two week range was $1.41-$3.06. The total market capitalization remained $73.60 billion. The stock is ahead its 52 week low with 75.18% and its last month price volatility remained 6.69%. Its beta coefficient was 1.38 with a target price of $6.00. In its share capital, the company has 34.07 million outstanding shares while 25.36 million shares have been floated in market. Its institutional ownership remained 1.14%. Its current year earnings per share grew with 29.91%.

Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) shares went 3.93% up and closed at $39.63 in the last trading session. The company is reportedly on track to reduce jobs in its home market of Israel even as local politicians oppose the company for paying too little in taxes.

The world’s largest maker of generic drugs has promised to reduce costs to save up to $2 billion in the next five years as part of a new strategy to increase long-term profitability. Ronny Gal, an analyst at Sanford C. Bernstein & Co, said that part of those savings will most likely need to come from Israel.

Its overall traded volume was 7.92 million shares. The stock’s opening price was $38.41, hitting the day high price of $39.66 and day low of $38.29.

TEVA has earnings per share of $2.24 and its price to earnings ratio was 17.69. The company has 3.88% returns on assets, 8.73% returns on equity and its return on investments is 5.29%.

Want to Learn How to Trade Penny Stocks? Click Here and Join Best Penny Stock Newsletter.

See More Updates on Our Blog: http://universalpennystocks.com/blog/index.php

About Universal Penny Stocks

universalpennystocks.com is an Independent Company, our focus is on small cap stocks that trade on OTCBB and OTC markets, and are mostly referred to as “penny stocks”. These are stocks that normally trade under $5 a share and could offer the greatest potential return on your short or long term investment. You must read our Disclaimer page for more information regarding conflicts of interest and the risks involved.

We try to spot stocks in all types of market conditions. In addition, we provide emerging small cap companies with profiling and investor relations services for compensation. If you believe your company is an emerging company, with a solid product, or a company that offers our members a profitable short or long term opportunity please feel free to send us an e-mail and we’ll review the company and reply to your inquiry promptly. Please provide as much information you believe we’ll need to review your request.